China MPS VI Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
MPS VI is a rare genetic disorder characterized by complete or partial lack of activity of the enzyme arylsulfatase B, encoded by the ARSB gene. Deficiency or absence of this enzyme activity leads to the accumulation of complex carbohydrates called glycosaminoglycans in the body. Abnormal accumulation of mucopolysaccharides leads to progressive involvement of multiple organ systems. The global Incidence of MPS VI is estimated to occur in 1 in 250,000 to 600,000 new-borns. The diagnosis age is 2-3 years. The projected lifespan of affected patients is About 20 years, for severe forms and more for milder forms.
China is a growing market for MPS VI due to factors such as increase in global incidence rate (1 in 250,000 to 600,000 new-borns). Other factors that are contributes to the growth of market are awareness campaign by various organizations, affordable reimbursement scenario for treatment, the growing necessity for advanced therapeutics and improved R&D activities.
However, there are some restraining factors for growth of MPS VI therapeutics market in China such as high cost of medicines, misdiagnosis of the disease and lack of innovative therapies.